Answers are grounded in this paper and cite their sources.
Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease.
No takes yet. Share an insight, caveat, or question.
Favorito et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: